Evidence map›Paper›PMID 34162424›Full record

ReviewStem cell research & therapy2021

Surfing the clinical trials of mesenchymal stem cell therapy in ischemic cardiomyopathy.

Iman Razeghian-Jahromi, Anthony G Matta, Ronan Canitrot, Mohammad Javad Zibaeenezhad, Mahboobeh Razmkhah, Anahid Safari, Vanessa Nader, Jerome Roncalli

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cell research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 70 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Iman Razeghian-JahromiCardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Anthony G MattaDepartment of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, Toulouse, France.
Ronan CanitrotDepartment of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, Toulouse, France.
Mohammad Javad ZibaeenezhadCardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mahboobeh RazmkhahShiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Anahid SafariStem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Vanessa NaderDepartment of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, Toulouse, France.
Jerome RoncalliDepartment of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, Toulouse, France. roncalli.j@chu-toulouse.fr.ORCID 0000-0002-4093-0435
Shiraz University of Medical Sciences · IRCentre Hospitalier Universitaire de Toulouse · FRHoly Spirit University of Kaslik · LBInstitut de Mathématiques de Toulouse · FRLebanese University · LB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While existing remedies failed to fully address the consequences of heart failure, stem cell therapy has been introduced as a promising approach. The present review is a comprehensive appraisal of the impacts of using mesenchymal stem cells (MSCs) in clinical trials mainly conducted on ischemic cardiomyopathy. The benefits of MSC therapy for dysfunctional myocardium are likely attributed to numerous secreted paracrine factors and immunomodulatory effects. The positive outcomes associated with MSC therapy are scar size reduction, reverse remodeling, and angiogenesis. Also, a decreasing in the level of chronic inflammatory markers of heart failure progression like TNF-α is observed. The intense inflammatory reaction in the injured myocardial micro-environment predicts a poor response of scar tissue to MSC therapy. Subsequently, the interval delay between myocardial injury and MSC therapy is not yet determined. The optimal requested dose of cells ranges between 100 to 150 million cells. Allogenic MSCs have different advantages compared to autogenic cells and intra-myocardial injection is the preferred delivery route. The safety and efficacy of MSCs-based therapy have been confirmed in numerous studies, however several undefined parameters like route of administration, optimal timing, source of stem cells, and necessary dose are limiting the routine use of MSCs therapeutic approach in clinical practice. Lastly, pre-conditioning of MSCs and using of exosomes mediated MSCs or genetically modified MSCs may improve the overall therapeutic effect. Future prospective studies establishing a constant procedure for MSCs transplantation are required in order to apply MSC therapy in our daily clinical practice and subsequently improving the overall prognosis of ischemic heart failure patients.

Indexed as

CardiomyopathiesMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMyocardial InfarctionHumansProspective StudiesClinical trialsIschemic cardiomyopathyMesenchymal stem cells

Identifiers

PMID34162424
PMCPMC8220796
OpenAlexW3177232349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.